九典制药(300705) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥397,864,203.25, representing a 50.97% increase compared to the same period last year[3]. - Net profit attributable to shareholders was ¥56,395,038.67, a significant increase of 152.17% year-on-year[3]. - The net profit excluding non-recurring gains and losses was ¥52,771,854.35, up 195.79% from the previous year[3]. - Basic earnings per share increased to ¥0.24, reflecting a growth of 140.00% compared to the same quarter last year[3]. - Total operating revenue for the current period reached ¥1,129,600,415.75, a significant increase from ¥656,824,252.48 in the previous period, representing a growth of approximately 72%[25]. - Net profit for the current period was ¥169,211,746.27, compared to ¥55,186,026.50 in the previous period, reflecting an increase of approximately 206%[28]. - Basic and diluted earnings per share for the current period were both ¥0.72, up from ¥0.24 in the previous period, marking a 200% increase[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,640,210,752.51, a 45.06% increase from the end of the previous year[3]. - Total assets reached ¥1,640,210,752.51, compared to ¥1,130,719,874.02 at the end of the previous year, marking a growth of 45%[19]. - Total liabilities increased to ¥576,051,829.19 from ¥295,037,659.68, indicating a rise of about 95%[24]. - Current liabilities increased to ¥286,725,953.00 from ¥180,959,561.14, a rise of 58.5%[20]. - Non-current liabilities decreased from ¥70,502,269.37 to ¥39,656,375.68, a reduction of 43.8%[20]. Cash Flow - Cash flow from financing activities showed a significant increase of 490.56%, totaling ¥283,748,349.99, primarily due to the issuance of convertible bonds[9]. - Cash flow from operating activities amounted to ¥1,228,947,707.34, compared to ¥694,178,138.48 in the previous period, showing an increase of about 77%[33]. - The net cash flow from financing activities was CNY 283,748,349.99, a significant improvement from a net outflow of CNY -72,651,373.62 previously[39]. - The total cash inflow from financing activities amounted to CNY 310,000,000.00, compared to CNY 9,500,000.00 in the previous period[39]. - The total cash outflow from operating activities was CNY 1,172,897,031.10, compared to CNY 629,251,967.53 in the previous period[36]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,245[10]. - The largest shareholder, Zhu Zhihong, holds 35.76% of shares, totaling 83,910,000 shares[10]. - The company has a total of 62,932,500 shares with restricted voting rights held by priority shareholders[10]. Research and Development - Research and development expenses rose to ¥90,708,588.17, a 52.02% increase year-on-year, indicating a focus on innovation[9]. - Research and development expenses for the current period totaled ¥90,708,588.17, compared to ¥59,667,670.00 in the previous period, representing a growth of approximately 52%[28]. Inventory and Receivables - Accounts receivable rose to ¥223,210,658.96, up from ¥164,284,293.84, indicating a year-over-year increase of 36%[17]. - Inventory increased to ¥210,486,409.83 from ¥153,117,867.75, reflecting a growth of 37.5%[17]. - The company reported a significant increase in other receivables, which rose to ¥7,779,310.78 from ¥1,025,216.92, a growth of 658%[17].